Estrogens and gonadal function in schizophrenia and related psychoses

Current Topics in Behavioral Neurosciences

Volumn 8, Issue , 2011, Pages 155-171

  Riecher Rössler, Anita ^a   Kulkarni, Jayashri ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Estradiol; Estrogens; Gonadal function; Psychoses; Schizophrenia

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; HALOPERIDOL; NORETHISTERONE; PLACEBO; PROGESTERONE;

ARTICLE; BASIC RESEARCH; BRAIN REGION; CANCER PREVENTION; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ESTROGEN BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; GONAD DYSFUNCTION; GONAD FUNCTION; HEART INFARCTION; HORMONE DETERMINATION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERESTROGENISM; HYPOPHYSIS GONAD SYSTEM; IRRITABILITY; LUNG EMBOLISM; NEUROPROTECTION; NIGHT SWEAT; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUERPERAL PSYCHOSIS; RISK ASSESSMENT; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SIDE EFFECT; SLEEP DISORDER; STROKE; ANIMAL; ESTROGEN THERAPY; FEMALE; GONAD; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SEXUAL DEVELOPMENT;

ANIMALS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GONADS; HUMANS; MALE; SCHIZOPHRENIA; SEX CHARACTERISTICS;

EID: 80053298318     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2010_100     Document Type: Article

References (77)

1. Ahokas A, Aito M, Rimon R (2000) Positive treatment effect of estradiol in postpartum psychosis: a pilot study. J Clin Psychiatry 61:166-9
2. Akhondzadeh S, Nejatisafa AA, Amini H, Mohammadi MR, Larijani B, Kashani L et al (2003) Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 27:1007-12
3. Althaus G, Pfuhlmann B, Franzek E (2000) The effect of the menstruation cycle on manifestations of pychiatric diseases. Fortschr Neurol Psychiatr 68:357-62
4. Balthazart J, Ball GF (2006) Is brain estradiol a hormone or a neurotransmitter? Trends Neurosci 29:241-9
5. Bergemann N, Parzer P, Nagl I, Salbach B, Runnebaum B, Mundt C et al (2002) Acute psychiatric admission and menstrual cycle phase in women with schizophrenia. Arch Womens Ment Health 5:119-26
6. Bergemann N, Parzer P, Runnebaum B, Resch F, Mundt C (2007a) Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol Med 37: 1427-36
7. Bergemann N, Abu-Tair F, Strowitzki T (2007b) Estrogen in the treatment of late-onset schizophrenia. J Clin Psychopharmacol 27:718-20
8. Bergemann N, Parzer P, Jaggy S, Auler B, Mundt C, Maier-Braunleder S (2008) Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial. Schizophr Bull 34:1172-81
9. Birkhäuser MH, Panay N, Archer DF, Barlow D, Burger H, Gambacciani M et al (2008) Updated practical recommendations for hormone replacement therapy in the peri-and postmenopause. Climacteric 11:108-23
10. Bleuler M (1943) Die spätschizophrenen Krankheitsbilder. Neurology 15:259-90
11. Braendle W, Breckwoldt M, Kuhl H (2001) Sexualhormone und Psyche-Ergebniosse des 2. Interdisziplinären Frankfurter Gesprächs zur Kontrazeption. Frauenarzt 42:154-60
12. Canuso CM, Goldstein JM, Wojcik J, Dawson R, Brandman D, Klibanski A et al (2002) Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res 111:11-20
13. Choi SH, Kang SB, Joe SH (2001) Changes in premenstrual symptoms in women with schizophrenia: a prospective study. Psychosom Med 63:822-9
14. Chua W, De Izquierdo S, Kulkarni J, Mortimer AM (2005) Estrogen for schizophrenia. Cochrane Database Syst Rev. doi:10.1002/14651858.CD0044719.pub2
15. Cohen RZ, Seeman MV, Gotowiec A, Kopala L (1999) Earlier puberty as a predictor of later onset of schizophrenia in women. Am J Psychiatry 156:1059-64
16. Craig MC, Maki PM, Murphy DG (2005) The Women's Health Initiative Memory Study: findings and implications for treatment. Lancet Neurol 4:190-4
17. Cyr M, Calon F, Morissette M, Di Paolo T (2002) Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J Psychiatry Neurosci 27:12-27
18. Davis SR (2002) The effects of tibolone on mood and libido. Menopause 9:162-70
19. Garcia-Segura L, Azcoitia I, Doncarlos L (2001) Neuroprotection by estradiol. Prog Neurobiol 63:29-60
20. Goldstein JM, Seidman LJ, O'Brien LM, Horton NJ, Kennedy DN, Makris N et al (2002) Impact of normal sexual dimorphisms on sex differences in structural brain abnormalities in schizophrenia assessed by magnetic resonance imaging. Arch Gen Psychiatry 59:154-64
21. Good KP, Kopala LC, Martzke JS, Fluker M, Seeman MV, Parish B et al (1999) Hormone replacement therapy in postmenopausal women with schizophrenia: preliminary findings. Schizophr Res 12:131
22. Grigoriadis S, Seeman MV (2002) The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can J Psychiatry 47:437-42
23. Häfner H (2005) Gender differences in schizophrenia. In: Bergemann N, Riecher-Rössler A (eds) Estrogen effects in psychiatric disorders. Springer, Wien, pp 53-94
24. Häfner H, Behrens S, De Vry J, Gattaz WF, Löffler W, Maurer K et al (1991a) Warum erkranken Frauen später an Schizophrenie? Erhöhung der Vulnerabilitätsschwelle durch Ö strogen. Nervenheilkunde 10:154-63
25. Häfner H, Riecher-Rössler A, Hambrecht M, Maurer K, Meissner S, Schmidtke A et al (1991b) Geschlechtsunterschiede bei schizophrenen Erkrankungen. Fortschr Neurol Psychiatr 59: 343-60
26. Häfner H, Riecher-Rössler A, An Der Heiden W, Maurer K, Fatkenheuer B, Löffler W (1993) Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia. Psychol Med 23:925-40
27. Halbreich U (2002) The spectrum of estrogens, estrogen agonists and serms. Int J Neuropsychopharmacol 5(Suppl 1):12
28. Harris AH (1997) Menstrually related symptom changes in women with schizophrenia. Schizophr Res 27:93-9
29. Hayeems R, Seeman MV (2005) Puberty and schizophrenia onset. In: Bergemann N, Riecher-Rössler A (eds) Estrogen effects in psychiatric disorders. Springer, Wien, p 95
30. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA (2002) Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 287:591-7
31. Hoff AL, Harris D, Faustman WO, Beal M, DeVilliers D, Mone RD et al (1996) A neuropsychological study of early onset schizophrenia. Schizophr Res 20:21-8
32. Hoff AL, Kremen WS, Wieneke MH, Lauriello J, Blankfeld HM, Faustman WO et al (2001) Association of estrogen levels with neuropsychological performance in women with schizophrenia. Am J Psychiatry 158:1134-9
33. Honigfeld G, Gillis R, Klett C (eds) (1976) NOSIE: nurses' observation scale for inpatient evaluation. NIMH, Rockville
34. Huber TJ, Rollnik J, Wilhelms J, von zur Muhlen A, Emrich HM, Schneider U (2001) Estradiol levels in psychotic disorders. Psychoneuroendocrinology 26:27-35
35. Ko YH, Joe SH, Cho W, Park JH, Lee JJ, Jung IK et al (2006) Estrogen, cognitive function and negative symptoms in female schizophrenia. Neuropsychobiology 53:169-75
36. Könnecke R, Häfner H, Maurer K, Löffler W, An der Heiden W (2000) Main risk factors for schizophrenia: increased familial loading and pre-and peri-natal complications antagonize the protective effect of oestrogen in women. Schizophr Res 44:81-93
37. Korhonen S, Saarijarvi S, Aito M (1995) Successful estradiol treatment of psychotic symptoms in the premenstrual phase: a case report. Acta Psychiatr Scand 92:237-8
38. Kulkarni J (2005) Clinical estrogen trials in patients with schizophrenia. In: Bergemann N, Riecher-Rössler A (eds) Estrogen effects in psychiatric disorders. Springer, Vienna, pp 107-23
39. Kulkarni J (2009) Oestrogen _ a new treatment approach for schizophrenia? Med J Aust 190: S37-8
40. Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D (1996) A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 20:247-52
41. Kulkarni J, Riedel A, de Castella AR, Fitzgerald PB, Rolfe TJ, Taffe J et al (2001) Estrogen-a potential treatment for schizophrenia. Schizophr Res 48:137-44
42. Kulkarni J, Gurvich C, Lee SJ, Gilbert H, Gavrilidis E, de Castella A et al (2010) Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 35(8):1142-1147
43. Labhart A (1978) Klinik der inneren Sekretion. Springer, Berlin
44. Lindamer LA, Lohr JB, Harris MJ, Jeste DV (1997) Gender, estrogen, and schizophrenia. Psychopharmacol Bull 33:221-8
45. Lindamer LA, Buse DC, Lohr JB, Jeste DV (2001) Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol Psychiatry 49:47-51
46. Lindamer LA, Buse DC, Auslander L, Unutzer J, Bartels SJ, Jeste DV (2003) A comparison of gynecological variables and service use among older women with and without schizophrenia. Psychiatr Serv 54:902-4
47. Louza MR, Marques AP, Elkis H, Bassitt D, Diegoli M, Gattaz WF (2004) Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophr Res 66:97-100
48. Maguire GA (2002) Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 63(Suppl 4):56-62
49. Mahe V, Dumaine A (2001) Oestrogen withdrawal associated psychoses. Acta Psychiatr Scand 104:323-31
50. Mall G (1960) Diagnostik und Therapie ovarieller Psychosen. Zentralbl Gesamte Neurol Psychiatr 155:250
51. McEwen B (2002) Interplay between membrane and genomic actions of estrogens. Int J Neuropsychopharmacol 5(Suppl 1):12
52. Neumann NU, Frasch K (2001) Olanzapine and pregnancy. 2 case reports. Nervenarzt 72:876-8
53. Oesterlund M (2002) The role of estrogens in neuropsychiatric disorders. Curr Opin Psychiatry 15:307-12
54. Oesterlund MK, Keller E, Hurd YL (2000) The human forebrain has discrete estrogen receptor alpha messenger RNA expression: high levels in the amygdaloid complex. Neuroscience 95:333-42
55. Overall J, Gorham D (1962) The brief psychiatric rating scale. Psychol Rep 10:799-812
56. Riecher A, Maurer K, Löffler W, Fätkenheuer B, An Der Heiden W, Munk-Jorgensen P (1991) Gender differences in age at onset and course of schizophrenic disorders. In: Häfner H, Gattaz W (eds) Search for the causes of schizophrenia. Springer, Berlin, pp 14-33
57. Riecher-Rössler A (2002) Oestrogen effects in schizophrenia and their potential therapeutic implications _ review. Arch Womens Ment Health 5:111-8
58. Riecher-Rössler A, de Geyter C (2007) The forthcoming role of treatment with oestrogens in mental health. Swiss Med Wkly 137:565-72
59. Riecher-Rössler A, Häfner H (1993) Schizophrenia and oestrogens-is there an association? Eur Arch Psychiatry Clin Neurosci 242:323-8
60. Riecher-Rössler A, Häfner H, Dutsch-Strobel A, Oster M, Stumbaum M, van Gulick-Bailer M et al (1994a) Further evidence for a specific role of estradiol in schizophrenia? Biol Psychiatry 36:492-4
61. Riecher-Rössler A, Häfner H, Stumbaum M, Maurer K, Schmidt R (1994b) Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 20:203-14
62. Riecher-Rössler A, Löffler W, Munk-Jorgensen P (1997) What do we really know about late-onset schizophrenia? Eur Arch Psychiatry Clin Neurosci 247:195-208
63. Riecher-Rössler A, Häfner H, Dütsch-Strobel A, Stumbaum M (1998) Gonadal function and its influence on psychopathology. A comparison of schizophrenic and non-schizophrenic female inpatients. Arch Womens Ment Health 1:15-26
64. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321-33
65. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM et al (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297:1465-77
66. Seeman MV (1996) Schizophrenia, gender, and affect. Can J Psychiatry 41:263-4
67. Sherwin BB (2005) Estrogen and memory in women: how can we reconcile the findings? Horm Behav 47:371-5
68. Smith S, Wheeler MJ, Murray R, O'Keane V (2002) The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 22:109-14
69. Stahl SM (2001a) Effects of estrogen on the central nervous system. J Clin Psychiatry 62:317-8
70. Stahl SM (2001b) Why drugs and hormones may interact in psychiatric disorders. J Clin Psychiatry 62:225-6
71. Thompson KN, Kulkarni J, Sergejew AA (2000) Extrapyramidal symptoms and oestrogen. Acta Psychiatr Scand 101:130-4
72. Vedder H, Behl C (2005) Estrogens in neuropsychiatric disorders: from physiology to pathophysiology. In: Bergemann N, Riecher-Rossler A (eds) Estrogen effects in psychiatric disorders. Springer, Wien, pp 1-30
73. von Zerssen D, Koeller D (1976) Klinische Selbstbeurteilungs-Skalen (KSb-Si) aus dem Münchener Psychiatrischen Informations-System (PSYCHIS München). Manual. Beltz, Weinheim
74. Warner MD, Walker AM, D'Souza DC, Lee D, Nasseri D, Peabody CA (2001) Lower prolactin bioactivity in unmedicated schizophrenic patients. Psychiatry Res 102:249-54
75. Weickert CS, Miranda-Angulo AL, Wong J, Perlman WR, Ward SE, Radhakrishna V et al (2008) Variants in the estrogen receptor alpha gene and its mRNA contribute to risk for schizophrenia. Hum Mol Genet 17:2293-309
76. Yonkers KA, Kando JC, Cole JO, Blumenthal S (1992) Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 149:587-95
77. Zhang-Wong JH, Seeman MV (2002) Antipsychotic drugs, menstrual regularity and osteoporosis risk. Arch Womens Ment Health 5:93-8